These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9375912)

  • 21. Adverse effects of disopyramide (Norpace): toxic interactions with other antiarrhythmic agents.
    Ellrodt G; Singh BN
    Heart Lung; 1980; 9(3):469-74. PubMed ID: 6901519
    [No Abstract]   [Full Text] [Related]  

  • 22. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
    O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
    Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.
    Tanabe T; Takahashi K; Yoshioka K; Goto Y
    Int J Cardiol; 1991 Sep; 32(3):303-12. PubMed ID: 1724233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of oral repetitive loading of disopyramide on acute-onset atrial fibrillation with concurrent monitoring of serum drug concentration.
    Kishikawa T; Maruyama T; Kaji Y; Sasaki Y; Kanaya S; Fujino T; Niho Y; Ishihara Y
    Int J Cardiol; 1999 Jan; 68(1):57-62. PubMed ID: 10077401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical studies of Norpace. Summarizing remarks.
    Fowler NO
    Angiology; 1975 Jan; 26(1 Pt 2):154-5. PubMed ID: 1090216
    [No Abstract]   [Full Text] [Related]  

  • 26. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
    Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
    J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy.
    Teraguchi M; Ikemoto Y; Kobayashi Y
    Circ J; 2002 Jul; 66(7):709-11. PubMed ID: 12135145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electric cardioversion of atrial fibrillation resulting in pulmonary oedema in patient with apical hypertrophic cardiomyopathy.
    Nawrocka I; Kaczyńska A; Abramczyk P
    Pol Merkur Lekarski; 2015 May; 38(227):278-9. PubMed ID: 26039023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
    Deano DA; Wu D; Mautner RK; Sherman RH; Ehsani AI; Rosen KM
    Chest; 1977 May; 71(5):597-606. PubMed ID: 856558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoglycaemia induced by disopyramide in a patient with Type 2 diabetes mellitus.
    Reynolds RM; Walker JD
    Diabet Med; 2001 Dec; 18(12):1009-10. PubMed ID: 11903405
    [No Abstract]   [Full Text] [Related]  

  • 31. Prophylaxis against atrial fibrillation after cardiac surgery: beneficial effect of perioperative metoprolol.
    Skiba MA; Pick AW; Chaudhuri K; Bailey M; Krum H; Kwa LJ; Rosenfeldt FL
    Heart Lung Circ; 2013 Aug; 22(8):627-33. PubMed ID: 23465653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of repetitive monomorphic ventricular tachycardia].
    Kurusu O; Kudou S; Nomoto J; Tanoiri T; Tokuhisa Y; Kubouchi Y; Sanada T; Komatsu C; Okamura T
    Kokyu To Junkan; 1992 Aug; 40(8):823-6. PubMed ID: 1529179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
    Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
    Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of percutaneous transluminal septal myocardial ablation on refractory paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy.
    Hosokawa Y; Takano H; Ohno T; Takayama M; Takano T
    Angiology; 2008; 59(3):329-34. PubMed ID: 18388103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy.
    Minardo JD; Heger JJ; Miles WM; Zipes DP; Prystowsky EN
    N Engl J Med; 1988 Aug; 319(5):257-62. PubMed ID: 3393179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.
    Ermakov S; Gerstenfeld EP; Svetlichnaya Y; Scheinman MM
    Heart Rhythm; 2017 Apr; 14(4):564-569. PubMed ID: 27939893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapy of arrhythmias in hypertrophic cardiomyopathy].
    Rapezzi C; Spirito P
    G Ital Cardiol; 1995 Nov; 25(11):1443-6. PubMed ID: 8682242
    [No Abstract]   [Full Text] [Related]  

  • 39. Possible acute and chronic synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy: a case report.
    Haruki S; Minami Y; Kajimoto K; Yashiro B; Suzuki T; Kawana M; Hagiwara N
    Eur J Heart Fail; 2010 Jan; 12(1):94-7. PubMed ID: 19942605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disopyramide: interactions with marcolide antibiotics.
    Prescrire Int; 2001 Oct; 10(55):151. PubMed ID: 11824433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.